Table 2.
Description of the answers of dermatologists to the questions concerning their awareness of studies on the role of oral photoprotectors in nonmelanoma skin cancer (NMSC).
| 7. Are You Aware of Scientific Studies/Trials That Have Demonstrated the Reduction of NMSC Due to One of the Products Indicated in Systemic Photoprotection? | 8. If So, Which of These Drugs or Supplements? Possible Answers: Astaxanthin, β-Carotene, Nicotinamide, Vitamin D, All of Them, None of Them. |
||||||
|---|---|---|---|---|---|---|---|
| Yes | Nicotinamide | Astaxanthin | Vitamin D3 | All of Them | None of Them | ||
| N (row%) | N (row%) | N (row%) | N (row%) | N (row%) | N (row%) | ||
| Overall | 88 (81.5) | 74 (68.5) | 1 (0.9) | 1 (0.9) | 16 (14.8) | 16 (14.8) | |
| Gender | Male | 43 (82.7) | 33 (63.5) | 1 (1.9) | 0 | 9 (17.3) | 9 (17.3) |
| Female | 45 (80.4) | 38 (67.9) | 0 | 1 (1.8) | 9 (16.1) | 8 (14.3) | |
| Years since end of training | <10 | 30 (90.9) | 28 (84.8) | 0 | 0 | 3 (9.1) | 2 (6.1) |
| 10–19 | 26 (92.9) | 23 (82.1) | 1 (3.6) | 0 | 2 (7.1) | 2 (7.1) | |
| ≥20 | 32 (68.1) * | 20 (42.6) | 0 | 1 (2.1) | 13 (27.7) | 13 (27.7) | |
| Area | Northern | 19 (79.2) | 43 (70.5) | 0 | 0 | 4 (16.7) | 8 (13.1) |
| Central | 52 (85.2) | 16 (66.7) | 0 | 1 (1.6) | 9 (14.8) | 4 (16.7) | |
| Southern | 17 (73.9) | 12 (52.2) | 1 (4.3) | 0 | 5 (21.7) | 5 (21.7) | |
| Workplace | Hospital | 13 (76.5) | 11 (67.4) | 1 (5.9) | 0 | 2 (11.8) | 3 (17.6) |
| University/research hospital | 40 (85.1) | 34 (72.3) | 0 | 1 (1.2) | 6 (12.8) | 6 (12.8) | |
| Local health department | 11 (73.3) | 10 (66.7) | 0 | 0 | 2 (13.3) | 3 (20.0) | |
| Private practice | 24 (82.8) | 16 (55.2) | 0 | 0 | 8 (27.6) | 5 (17.2) | |
* p < 0.01 from chi-square test compared with the categories “<10” and “10–19” grouped together.